Systemic lupus erythematosus: pharmacological developments and recommendations for a therapeutic strategy (Q37038984)

17 August 2017

1 reference

title

Systemic lupus erythematosus: pharmacological developments and recommendations for a therapeutic strategy (English)

1 reference

systemic lupus erythematosus

17 August 2017

1 reference

1 reference

2

David A Isenberg

1 reference

17 August 2017

Jose Maria Pego-Reigosa

series ordinal

1

1 reference

PubMed ID

18095917

17 August 2017

language of work or name

English

0 references

publication date

1 January 2008

1 reference

Expert Opinion on Investigational Drugs

17 August 2017

1 reference

17 August 2017

17

1 reference

17 August 2017

1

1 reference

17 August 2017

31-41

1 reference

The 1982 revised criteria for the classification of systemic lupus erythematosus

17 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.31

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.31

Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.31

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.31

Sequential therapies for proliferative lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.31

Mycophenolate mofetil as a treatment for autoimmune haemolytic anaemia in patients with systemic lupus erythematosus and antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.31

Refractory immune thrombocytopenia in systemic lupus erythematosus: response to mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.31

Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.31

Mycophenolate sodium for subacute cutaneous lupus erythematosus resistant to standard therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.31

The central and multiple roles of B cells in lupus pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.31

Increased frequency of pre-germinal center B cells and plasma cell precursors in the blood of children with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.31

Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.31

An open study of B lymphocyte depletion in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.31

B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.31

Repeated B cell depletion in treatment of refractory systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.31

B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.31

The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.31

Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.31

CD22, a B lymphocyte-specific adhesion molecule that regulates antigen receptor signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.31

Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.31

BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.31

BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.31

T cell costimulation by the TNF ligand BAFF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.31

BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.31

Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.31

B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.31

Correlation of the expression levels of BLyS and its receptors mRNA in patients with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.31

Conjugates of double-stranded oligonucleotides with poly(ethylene glycol) and keyhole limpet hemocyanin: a model for treating systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.31

Elimination of self-reactive B lymphocytes proceeds in two stages: arrested development and cell death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.31

LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.31

Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.31

Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.31

Signals and signs for lymphocyte responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.31

Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.31

Treatment of murine lupus with CTLA4Ig

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.31

Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.31

Prevention of renal damage in murine lupus nephritis by CTLA-4Ig and cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.31

CD40 AND CD154 IN CELL-MEDIATED IMMUNITY

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.31

The role of CD40 in the regulation of humoral and cell-mediated immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.31

Tumour necrosis factor-alpha in murine autoimmune 'lupus' nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.31

Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.31

Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.31

Anti-dsDNA antibody up-regulates interleukin 6, but not cyclo-oxygenase, gene expression in glomerular mesangial cells: a marker of immune-mediated renal damage?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.31

Interleukin 6 promotes murine lupus in NZB/NZW F1 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.31

Raised levels of interleukin 6 in systemic lupus erythematosus correlate with anaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.31

Women in academic rheumatology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.31

Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.31

The type I interferon system in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.31

C5a promotes development of experimental lupus nephritis which can be blocked with a specific receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.31

Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.31

High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.31

High-dose cyclophosphamide for severe systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.31

Clinical amelioration of murine lupus by a peptide based on the complementarity determining region-1 of an autoantibody and by cyclophosphamide: similarities and differences in the mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.31

Autoimmune Diseases Induced by TNF-Targeted Therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.31

Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.1.31

21 January 2018

Identifiers

DOI

10.1517/13543784.17.1.31

1 reference

17 August 2017

1 reference

PubMed ID

18095917